Development of housing for socially weak people in Slezská Ostrava

Import 29/09/2010Tato bakalářská práce se zabývá výběrem lokalit pro bydlení sociálně slabých skupin obyvatel v městské části Slezská Ostrava, včetně návrhu objektů pro levné bydlení a startovacího bydlení pro mladé rodiny. Teoretická část bakalářské práce se zabývá problematikou potřeby sociálního bydlení ve vybrané lokalitě, stanovuje principy pro výstavbu, zdůvodňuje výběr území a popisuje vnitřní urbanistické vazby uvnitř lokality, jakož i vazby k bezprostřednímu a širšímu okolí. Práce se zamýšlí nad řešením okolí bytových domů s ohledem na sportovní a volnočasové využití všech obyvatel. Praktická část obsahuje urbanistický návrh lokality s napojením na stávající části města a stávající infrastrukturu. Detailně řeší typologický návrh bytového domu se zaměřením na pohodlné bydlení. Součástí návrhu je také urbanistické a technické řešení okolí domu včetně řešení parkovacích a komunikačních ploch.This baccalaureate work deal with by selection localities for living social weak groups inhabitant in town parts Silesian Ostrava, inclusive proposal objects for cheap living and starting living for cub families. Theoretic part baccalaureate work deal with problems needs social living in choice locality, establishes principles for build - up, give reasons for selection territory and describes inner urban design bindings inside locations, as well as ties to immediate and wider surroundings. Work aims above solving surroundings housing home with reference to sports and free time-time usage of all inhabitant. Practical part includes urban design proposal locations with inosculation on current outskirts and current infrastructure. In detail smoothing - out typological proposal housing house with a view to comfortable living. Part of proposal is also urban design and technical solving surroundings house inclusive solving parking and communications surfaces.Prezenční222 - Katedra městského inženýrstvívýborn

Existing specialty schools as leverage for behavioral sciences research on teaching and learning in STEM fields

The National Science Foundation has requested comments and proposals that outline challenge questions for the next decade in behavioral sciences research. At the same time, the NSF has joined the President\u27s Council of Advisors on Science and Technology as well as the National Academy of Sciences in issuing reports first identifying the need for specialized STEM education as a strategic necessity and then proposing the establishment of an additional 1000 specialized STEM schools. A common theme in these reports is that foundational work must be conducted to establish effective organizational and instructional practices for these schools. The authors of this paper serve as directors of a national organization of 92 such schools, and as representatives of two of the schools used as exemplars in the PCAST report they challenge the National Science Foundation to engage and extend existing research relationships with these willing laboratory schools as a means to accelerate the work in the learning and behavioral sciences that must be conducted for this national endeavor. Full project information available at: http://www.nsf.gov/sbe/sbe_2020/submission_detail.cfm?upld_id=28

Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity

Natural killer (NK) cells are powerful effector cells that can be directed to eliminate tumor cells through tumor-targeted monoclonal antibodies (mAbs). Some tumor-targeted mAbs have been successfully applied in the clinic and are included in the standard of care for certain malignancies. Strategies to augment the antitumor response by NK cells have led to an increased understanding of how to improve their effector responses. Next-generation reagents, such as molecularly modified mAbs and mAb-cytokine fusion proteins (immunocytokines, ICs) designed to augment NK-mediated killing, are showing promise in preclinical and some clinical settings. Continued research into the antitumor effects induced by NK cells and tumor-targeted mAbs suggests that additional intrinsic and extrinsic factors may influence the antitumor response. Therefore more research is needed that focuses on evaluating which NK cell and tumor criteria are best predictive of a clinical response and which combination immunotherapy regimens to pursue for distinct clinical settings

Immunotherapy of Neuroblastoma: Facts and Hopes

While the adoption of multimodal therapy including surgery, radiation, and aggressive combination-chemotherapy has improved outcomes for many children with high-risk neuroblastoma, we appear to have reached a plateau in what can be achieved with cytotoxic therapies alone. Most children with cancer, including high-risk neuroblastoma, do not benefit from treatment with immune-checkpoint-inhibitors (ICI) that have revolutionized the treatment of many highly immunogenic adult solid tumors. This likely reflects the low tumor mutation burden as well as the downregulated MHC-I that characterizes most high-risk neuroblastomas. For these reasons, neuroblastoma represents an immunotherapeutic challenge that may be a model for the creation of effective immunotherapy for other "cold" tumors in children and adults that do not respond to ICI. The identification of strong expression of the disialoganglioside, GD2, on the surface of nearly all neuroblastoma cells provided a target for immune recognition by anti-GD2 mAbs which recruit Fc-receptor-expressing innate immune cells that mediate cytotoxicity or phagocytosis. Adoption of anti-GD2 antibodies into both upfront and relapse treatment protocols has dramatically increased survival rates and altered the landscape for children with high-risk neuroblastoma. This review describes how these approaches have been expanded to additional combinations and forms of immunotherapy that have already demonstrated clear clinical benefit. We also describe the efforts to identify additional immune targets for neuroblastoma. Finally we summarize newer approaches being pursued that may well help both innate and adaptive immune cells, endogenous or genetically engineered, to more effectively destroy neuroblastoma cells, in order to better induce complete remission and prevent recurrence